PlainPharmaWatch

CMS Open Payments · Tool

SPR Therapeutics, Inc vs Vesalio, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Vesalio, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,574, versus 200 for the other company. Its single largest recorded recipient represents 25.0% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

SPR Therapeutics, Inc
HHI 200 · top recipient 6.0%
Ranked #1,557 of 1,838 companies by HHI
Vesalio, Inc.
HHI 1,574 · top recipient 25.0%
Ranked #845 of 1,838 companies by HHI

Payment Overview

Total Payments
$16.2M
% of Industry
0.1%
Transactions
8,545
Avg per Transaction
$1.9K
Recipients
8,284
Avg per Recipient
$2.0K
Payment Types
3
Top Payment Type
Consulting Fee
Company B

Vesalio, Inc.

Total Payments
$16.4M
% of Industry
0.1%
Transactions
38
Avg per Transaction
$432.9K
Recipients
18
Avg per Recipient
$913.9K
Payment Types
2
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

SPR Therapeutics, Inc vs Vesalio, Inc. - total reported payments in CMS Open Payments PY2024

Vesalio, Inc.$16.4MSPR Therapeutics, Inc$16.2M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

SPR Therapeutics, Inc

Consulting Fee $565.2K

50.0%

Food and Beverage $328.9K

29.1%

Travel and Lodging $236.9K

20.9%

Vesalio, Inc.

Compensation for Services Other Than Consulting $23.0K

63.9%

Consulting Fee $13.0K

36.1%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

SPR Therapeutics, Inc

  1. 1

    CHRISTOPHER GILMORE

    $67,899.20 · 49 txns

  2. 2

    AMITABH GULATI

    $65,300.86 · 61 txns

  3. 3

    DAVID GUTIERREZ

    $48,526.34 · 95 txns

  4. 4

    Grant Chen

    $40,947.26 · 45 txns

  5. 5

    DAVID REECE

    $39,024.63 · 56 txns

Vesalio, Inc.

  1. 1

    Ameer Hassan

    $9,000.00 · 2 txns

  2. 2

    Nick Abedi

    $8,000.00 · 4 txns

  3. 3

    Naiem Nassiri

    $4,500.00 · 3 txns

  4. 4

    SHAHID NIMJEE

    $3,500.00 · 2 txns

  5. 5

    Halim Yammine

    $3,000.00 · 2 txns

Summary Comparison

Metric SPR Therapeutics, Inc Vesalio, Inc.
Total Payments $16.2M $16.4M
% of Industry Total 0.1% 0.1%
Transaction Count 8,545 38
Avg per Transaction $1.9K $432.9K
Recipient Count 8,284 18
Avg per Recipient $2.0K $913.9K
Payment Type Count 3 2
Top Payment Type Consulting Fee Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.